Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
T Sen, N Takahashi, S Chakraborty, N Takebe… - Nature Reviews …, 2024 - nature.com
Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a
dismal prognosis, with only modest advances in therapeutic strategies over the past several …
dismal prognosis, with only modest advances in therapeutic strategies over the past several …
Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions
H Deng, Y Han, L Liu, H Zhang, D Liu… - Journal of Medicinal …, 2024 - ACS Publications
As a tripartite cell death switch, B-cell lymphoma protein 2 (Bcl-2) family members precisely
regulate the endogenous apoptosis pathway in response to various cell signal stresses …
regulate the endogenous apoptosis pathway in response to various cell signal stresses …
[HTML][HTML] Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
Abstract BCL-X L and BCL-2 are key anti-apoptotic proteins and validated cancer targets.
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …
753B is a novel BCL-X L/BCL-2 proteolysis targeting chimera (PROTAC) that targets both …
Nanoliposomal Bcl-xL proteolysis-targeting chimera enhances anti-cancer effects on cervical and breast cancer without on-target toxicities
J Zhang, B Zhang, C Pu, J Cui, K Huang… - … Composites and Hybrid …, 2023 - Springer
Bcl-xL is a well-characterized target gene of cancer. DT2216, a selective proteolysis-
targeting chimera (PROTAC) has been developed for targeting Bcl-xL without causing …
targeting chimera (PROTAC) has been developed for targeting Bcl-xL without causing …
PROTACs: A novel strategy for cancer drug discovery and development
Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …
discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists …
Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy
Y Jiang, J Xie, Q Cheng, Z Cai, K Xu, W Lu… - International …, 2024 - Elsevier
Background A minority of patients with extensive-stage small cell lung cancer (ES-SCLC)
exhibit prolonged survival following first-line chemoimmunotherapy, which warrants the use …
exhibit prolonged survival following first-line chemoimmunotherapy, which warrants the use …
PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer
BCL-xL and BCL-2 are validated therapeutic targets in small-cell lung cancer (SCLC).
Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) …
Targeting these proteins with navitoclax (formerly ABT263, a dual BCL-xL/2 inhibitor) …
Therapy-induced senescence is finally escapable, what is next?
T Saleh - Cell Cycle, 2024 - Taylor & Francis
Several breakthrough articles have recently confirmed the ability of tumor cells to escape the
stable cell cycle arrest imposed by Therapy-Induced Senescence (TIS). Subsequently …
stable cell cycle arrest imposed by Therapy-Induced Senescence (TIS). Subsequently …
Protein degraders-from thalidomide to new PROTACs
T Ito - The Journal of Biochemistry, 2024 - academic.oup.com
Recently, the development of protein degraders (protein-degrading compounds) has
prominently progressed. There are two remarkable classes of protein degraders: proteolysis …
prominently progressed. There are two remarkable classes of protein degraders: proteolysis …
Comprehensive analysis of the function of helicobacter-associated ferroptosis gene YWHAE in gastric cancer through multi-omics integration, molecular docking, and …
D Liu, J Peng, J Xie, Y Xie - Apoptosis, 2024 - Springer
Gastric cancer is strongly associated with Helicobacter pylori (H. pylori) infection. However,
the molecular mechanisms underlying the development of gastric cancer in the context of H …
the molecular mechanisms underlying the development of gastric cancer in the context of H …